Calamos Advisors LLC increased its holdings in Biogen Inc. (NASDAQ:BIIB) by 2.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 28,805 shares of the biotechnology company’s stock after buying an additional 713 shares during the period. Calamos Advisors LLC’s holdings in Biogen were worth $7,817,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Pathstone Family Office LLC bought a new position in Biogen in the 1st quarter worth approximately $102,000. Prentiss Smith & Co. Inc. boosted its holdings in Biogen by 14.9% in the 2nd quarter. Prentiss Smith & Co. Inc. now owns 385 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 50 shares during the period. Independent Portfolio Consultants Inc. boosted its holdings in Biogen by 93.2% in the 2nd quarter. Independent Portfolio Consultants Inc. now owns 454 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 219 shares during the period. Winfield Associates Inc. boosted its holdings in Biogen by 16.8% in the 1st quarter. Winfield Associates Inc. now owns 467 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 67 shares during the period. Finally, Carroll Financial Associates Inc. boosted its holdings in Biogen by 1.2% in the 2nd quarter. Carroll Financial Associates Inc. now owns 496 shares of the biotechnology company’s stock valued at $134,000 after purchasing an additional 6 shares during the period. 87.26% of the stock is owned by institutional investors.
Several research analysts have commented on BIIB shares. Vetr raised shares of Biogen from a “buy” rating to a “strong-buy” rating and set a $311.67 price target for the company in a report on Tuesday, June 27th. Deutsche Bank AG started coverage on shares of Biogen in a report on Friday, June 23rd. They issued a “buy” rating and a $315.00 price target for the company. Robert W. Baird reissued a “hold” rating and issued a $290.00 price target on shares of Biogen in a report on Friday, August 25th. Credit Suisse Group set a $300.00 price target on shares of Biogen and gave the company a “hold” rating in a report on Friday, July 14th. Finally, Cantor Fitzgerald reissued a “hold” rating and issued a $277.00 price target on shares of Biogen in a report on Thursday, May 25th. Thirteen analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company’s stock. Biogen presently has a consensus rating of “Buy” and an average price target of $331.53.
TRADEMARK VIOLATION WARNING: “Calamos Advisors LLC Has $7.82 Million Position in Biogen Inc. (BIIB)” was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://transcriptdaily.com/2017/09/17/calamos-advisors-llc-has-7-82-million-position-in-biogen-inc-biib.html.
In other news, EVP Susan H. Alexander sold 4,974 shares of the stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $290.01, for a total value of $1,442,509.74. Following the sale, the executive vice president now owns 22,258 shares of the company’s stock, valued at $6,455,042.58. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Susan H. Alexander sold 7,758 shares of the stock in a transaction on Wednesday, July 19th. The shares were sold at an average price of $285.00, for a total transaction of $2,211,030.00. Following the completion of the sale, the executive vice president now directly owns 27,232 shares in the company, valued at approximately $7,761,120. The disclosure for this sale can be found here. Corporate insiders own 0.32% of the company’s stock.
Shares of Biogen Inc. (BIIB) opened at 321.26 on Friday. Biogen Inc. has a one year low of $244.28 and a one year high of $330.00. The company has a market cap of $67.92 billion, a price-to-earnings ratio of 21.08 and a beta of 0.77. The firm has a 50-day moving average of $298.79 and a 200-day moving average of $278.33.
Biogen (NASDAQ:BIIB) last announced its earnings results on Tuesday, July 25th. The biotechnology company reported $5.04 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $4.36 by $0.68. Biogen had a net margin of 28.10% and a return on equity of 37.42%. The business had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $2.81 billion. During the same quarter in the prior year, the firm posted $5.21 earnings per share. The business’s revenue for the quarter was up 6.4% on a year-over-year basis. Equities research analysts forecast that Biogen Inc. will post $21.48 EPS for the current fiscal year.
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.